Article Text

Download PDFPDF
Rofecoxib v naproxen v placebo in rheumatoid arthritis: gastroduodenal ulcer incidence

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

COX-2 inhibitors are as effective as non-selective NSAIDs and are well tolerated. Naproxen reduces prostaglandin synthesis in the gastric mucosa by 70% whereas rofecoxib has no effect. Endoscopic studies have shown that rofecoxib is associated with significantly less risk of upper gastrointestinal complications than are the non-selective drugs in patients with osteoarthritis. Similar findings have been reported in patients with rheumatoid arthritis. Now a large international study has produced similar results.

At 48 …

View Full Text